EU Industry Renews Call For Digital Regulatory Infrastructure
‘No Further Excuse To Delay’ Says Medicines For Europe
Medicines for Europe has renewed its call for a modern digital regulatory infrastructure in the wake of the COVID-19 pandemic to bolster communication and preparedness for future health crises, insisting that there is “no further excuse to delay.”
You may also be interested in...
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.